Related Experiment Video
Updated: Jul 10, 2025
07:55
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
776
IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment
Pengcheng Yi1,2, Wenjun Yu3, Yanhong Xiong1,2
1Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province, P.R. China.
Molecular Cancer Therapeutics
|November 21, 2023
Summary
Interleukin 35 (IL-35) is an inhibitory cytokine found in the tumor microenvironment, promoting cancer progression and immune escape. Targeting IL-35 offers a promising new strategy for cancer therapy.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Interleukin 35 (IL-35) is an inhibitory cytokine implicated in cancer progression.
- Elevated IL-35 levels are observed in the tumor microenvironment (TME) and peripheral blood of cancer patients.
- IL-35 contributes to tumor immune escape by recruiting immunosuppressive cells like myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs).
Approach:
- This review synthesizes current research on the role of IL-35 in the TME.
- It examines the mechanisms by which IL-35 promotes tumor growth, immune suppression, and angiogenesis.
- The potential of IL-35 as a therapeutic target and prognostic factor is explored.
Key Points:
- IL-35 facilitates tumor immune escape by promoting immunosuppressive cell phenotypes and tumor angiogenesis.
- Neutralizing IL-35 antibodies have shown potential in enhancing chemotherapy efficacy and reducing tumor vascularization in preclinical models.
- IL-35 plays a critical role in the complex interplay between tumors and immune cells within the TME.
Conclusions:
- Targeting IL-35 presents a promising therapeutic strategy for overcoming challenges in cancer treatment, including resistance to immunotherapy and adverse effects of radiotherapy.
- IL-35 may serve as an independent prognostic biomarker for various cancers.
- Further research into IL-35's interactions within the TME could yield novel cancer treatment options.
Related Concept Videos
01:27Tumor Immunotherapy
530
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
530
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
01:24T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
01:27Cytotoxic T Cells-mediated Immune Response
924
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
924
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K